Literature DB >> 26403399

REPAIR EFFECTS OF UMBILICAL CORD MESENCHYMAL STEM CELLS ON PODOCYTE DAMAGE OF IgA NEPHROPATHY.

D W Zhang1, H Qiu1, Y M Mei1, H Fu1, H G Zheng1.   

Abstract

This study aimed to explore the influence of umbilical cord mesenchymal stem cells (UMSC) on stem cell homing and glomerular mesangial cell (GMC) after intravenous injection performed on mice tails with IgA nephropathy (IgAN) and its possible mechanism, which provide a new way and theoretical basis for the application of stem cell transplantation (SCT) in kidney disease treatment. Specific pathogen free (SPF) male Kunming mice were randomly divided into groups. A complex method applying bovine serum albumin (BSA) gavage, hypodermic injection of CCl4 and lipopolysaccharide (LPS) was used for building IgAN mice model. In addition, vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF) and cluster of differentiation (CD) 44 were observed by Masson staining and detected with immunohistochemistry (IHC) to confirm homing and location of mesenchymal stem cells (MSCs). Moreover, Western Blot was used for detecting VEGF and CTGF so as to explore the possible mechanism of applying UMSC in treating IgAN. Masson staining indicated that fibrosis degree of MSCs in treatment group was significantly lower than in negative control group after stem cell treatment. Routine urine test explained that proteinuria in treatment group were (7.15±0.31), (4.87±0.22), (2.95±0.16) g/24 h and (12.00±1.38) g/24 h in model group (P less than 0.05). MSCs were observed to be located in glomerulus and renal interstitium by IHC detection of CD44 and IHC qualitative observation of VEGF and CTGF had different positive expressions in three groups. Furthermore, different expressions of VEGF and CTGF were observed quantitatively by Western Blot. Fibrosis degree of renal tissue relieves, hematuresis and proteinuria eases and IgAN symptoms obviously improve after UMSC treatment, which hints that the treatment of HUMSC has protective effect on IgAN mice model.

Entities:  

Mesh:

Year:  2015        PMID: 26403399

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  6 in total

1.  Case report: effect of umbilical cord mesenchymal stem cells on immunoglobulin A nephropathy after acute renal failure.

Authors:  Neil H Riordan; Richard A Ambrozic; Jorge Paz-Rodríguez
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

Review 2.  Extracellular Vesicles Released from Stem Cells as a New Therapeutic Strategy for Primary and Secondary Glomerulonephritis.

Authors:  Marco Quaglia; Guido Merlotti; Laura Fornara; Andrea Colombatto; Vincenzo Cantaluppi
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

3.  Toll-like Receptor 4 Signaling Pathway in the Protective Effect of Pioglitazone on Experimental Immunoglobulin A Nephropathy.

Authors:  Jia-Nan Zou; Jing Xiao; Sha-Sha Hu; Chen-Sheng Fu; Xiao-Li Zhang; Zhen-Xing Zhang; Yi-Jun Lu; Wei-Jun Chen; Zhi-Bin Ye
Journal:  Chin Med J (Engl)       Date:  2017-04-20       Impact factor: 2.628

Review 4.  Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence.

Authors:  Anna Julie Peired; Alessandro Sisti; Paola Romagnani
Journal:  Stem Cells Int       Date:  2016-09-19       Impact factor: 5.443

Review 5.  Elevated Numbers of Circulating Very Small Embryonic-Like Stem Cells (VSELs) and Intermediate CD14++CD16+ Monocytes in IgA Nephropathy.

Authors:  Andrzej Eljaszewicz; Katarzyna Kleina; Kamil Grubczak; Urszula Radzikowska; Paula Zembko; Paulina Kaczmarczyk; Marlena Tynecka; Karolina Dworzanczyk; Beata Naumnik; Marcin Moniuszko
Journal:  Stem Cell Rev Rep       Date:  2018-10       Impact factor: 5.739

6.  Ameliorating role of microRNA-378 carried by umbilical cord mesenchymal stem cells-released extracellular vesicles in mesangial proliferative glomerulonephritis.

Authors:  Wenbiao Chen; Feng Zhang; Xianliang Hou; Huixuan Xu; Donge Tang
Journal:  Cell Commun Signal       Date:  2022-03-09       Impact factor: 5.712

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.